SS
SPRB

Steve Schonfeld’s Spruce Biosciences SPRB Stock Holding History

Steve Schonfeld’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,767
Closed -$2.16M – 2793
2025
Q4 		$2.16M Buy
+24,767
New +$2.65M 0.01% 849

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Steve Schonfeld's SPRB Position: Q1 2026 in Review

Steve Schonfeld sold out of Spruce Biosciences (SPRB) in Q1 2026, closing a stake of 24,767 shares — an estimated $2.16M sold.

Steve Schonfeld first reported a position in SPRB in Q4 2025 and held it in 1 quarter. The position peaked at $2.16M in Q4 2025. 32 funds tracked by Wall St. Rank hold SPRB as of Q1 2026.

  • Steve Schonfeld reported no remaining Spruce Biosciences position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 24,767 Spruce Biosciences shares in Q1 2026, an estimated $2.16M.
  • Steve Schonfeld first reported a position in Spruce Biosciences in Q4 2025 and held it in 1 quarter.
  • Steve Schonfeld's Spruce Biosciences position peaked at $2.16M in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.